⌘K

Login Start Free

Home/Filings/4/0000950170-24-002515

4//SEC Filing

Lebwohl David 4

Accession 0000950170-24-002515

CIK 0001652130other

View on SEC.gov Company Profile

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 4:50 PM ET

Size

4.8 KB

Accession

0000950170-24-002515

Insider Transaction Report

Form 4

Period: 2024-01-03

Intellia Therapeutics, Inc.NTLA

EVP, Chief Medical Officer

Transactions

Sale
Common Stock
2024-01-03$29.46/sh−5,843$172,135→ 54,372 total

Footnotes (1)

[F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1

filerCIK 0001810882

Filing Metadata

Form type: 4
Filed: Jan 4, 7:00 PM ET
Accepted: Jan 5, 4:50 PM ET
Size: 4.8 KB

View on SEC.gov